Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …

The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

Advances in molecular biology, microfluidics and bioinformatics have empowered the study
of thousands or even millions of individual cells from malignant tumours at the single-cell …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …

Cytokines are secreted or membrane-presented molecules that mediate broad cellular
functions, including development, differentiation, growth and survival. Accordingly, the …

T memory stem cells (T SCM) display increased self-renewal and prolonged survival
capabilities, thus preventing T cell exhaustion and promoting effective anti-tumor T cell …

Chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy for
the treatment of hematological malignancies. However, in patients with solid tumors …

Cytokines are a class of potent immunoregulatory proteins that are secreted in response to
various stimuli and act locally to regulate many aspects of human physiology and disease …

This single-arm, phase I dose-escalation trial (NCT02983045) evaluated
bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus …

Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …